News >

Expanded Use of Gleevec Approved in Patients With GIST

Ben Leach
Published: Wednesday, Feb 01, 2012

Imatinib (Gleevec)

The FDA approves imatinib after the surgical removal of KIT-positive GISTs.

The FDA granted regular approval for imatinib (Gleevec) for treating patients after the surgical removal of CD117-positive (KIT-positive) gastrointestinal stromal tumors (GISTs).

Dr. Joensuu Discusses Imatinib for GIST
“I consider [the overall survival rate] a very high figure, remembering that these patients had high-risk GIST, and in historical data, the risk of recurrence is greater than 50%,” said Heikki Joensuu, MD, PhD, professor of oncology, Helsinki University Central Hospital, Finland, at the 2011 ASCO meeting.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Advances in™ BRAF/MEK Inhibitors for the Treatment of Advanced MelanomaMay 31, 20191.5
Publication Bottom Border
Border Publication
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Oncology Nursing News
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

Conference Coverage
OncLive TV
Peer Exchange
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Press Releases
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.